Table 4.

Studies of ongoing randomized trials to assess optimal clopidogrel duration.

Study	Patient population	Clopidogrel duration (months)	Primary endpoint
ISAR-SAFE [64]	Patients on clopidogrel 6 months alter DES	6 versus 12	Composite of death, MI, ST, stroke and major bleeding
DAPT [65]	All-comers	12 versus 30	Composite of death, MI, SI, stroke and major bleeding
DAPT-STEMI	All STEMI patients	6 versus 12	MACCE
SECURITY	Second-generation DES	6 versus 12	Definite/probable ST
RESET	All-comers	3	Composite of cardiovascular death, MI, ST and major bleeding
OPTIMIZE	Stable CAD and NSTEMI	3 versus 12	Composite of death, MI, stroke and major bleeding

ISAR-SAFE: Intracoronary Stenting and Antithrombotic Regimen: Safety and Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting; DAPT: Dual Antiplatelet Therapy Study; STEMI: ST Elevation Myocardial Infarction; SECURITY: SECond generation drUg-eluting stents implantation followed by six-versus twelve-month dual antIplatElet therapy; RESET: A New Strategy Regarding Discontinuation of Dual Antiplatelets; OPTIMIZE: Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus Eluting Stent in the Real World Clinical Practice; DES: drug-eluting stent; CAD: coronary artery disease; NSTEMI: non-ST elevation myocardial infarction; MI: myocardial infarction; ST: stent thrombosis; MACCE: major adverse cardiovascular and cerebrovascular events.